Sign In
Buy JNJ
Johnson & Johnson Earnings Calls
| Release date | Oct 14, 2025 |
| EPS estimate | $2.76 |
| EPS actual | $2.80 |
| EPS Surprise | 1.45% |
| Revenue estimate | 23.755B |
| Revenue actual | 23.993B |
| Revenue Surprise | 1.00% |
| Release date | Jul 16, 2025 |
| EPS estimate | $2.68 |
| EPS actual | $2.77 |
| EPS Surprise | 3.36% |
| Revenue estimate | 22.854B |
| Revenue actual | 23.743B |
| Revenue Surprise | 3.89% |
| Release date | Apr 15, 2025 |
| EPS estimate | $2.58 |
| EPS actual | $2.77 |
| EPS Surprise | 7.36% |
| Revenue estimate | 21.559B |
| Revenue actual | 21.893B |
| Revenue Surprise | 1.55% |
| Release date | Jan 22, 2025 |
| EPS estimate | $1.99 |
| EPS actual | $2.04 |
| EPS Surprise | 2.51% |
| Revenue estimate | 22.431B |
| Revenue actual | 22.52B |
| Revenue Surprise | 0.396% |
Last 4 Quarters for Johnson & Johnson
Below you can see how JNJ performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jan 22, 2025 |
| Price on release | $145.27 |
| EPS estimate | $1.99 |
| EPS actual | $2.04 |
| EPS surprise | 2.51% |
| Date | Price |
|---|---|
| Jan 15, 2025 | $144.97 |
| Jan 16, 2025 | $147.77 |
| Jan 17, 2025 | $147.03 |
| Jan 21, 2025 | $148.15 |
| Jan 22, 2025 | $145.27 |
| Jan 23, 2025 | $146.64 |
| Jan 24, 2025 | $146.82 |
| Jan 27, 2025 | $152.91 |
| Jan 28, 2025 | $150.38 |
| 4 days before | 0.207% |
| 4 days after | 3.52% |
| On release day | 0.94% |
| Change in period | 3.73% |
| Release date | Apr 15, 2025 |
| Price on release | $153.62 |
| EPS estimate | $2.58 |
| EPS actual | $2.77 |
| EPS surprise | 7.36% |
| Date | Price |
|---|---|
| Apr 09, 2025 | $150.97 |
| Apr 10, 2025 | $148.69 |
| Apr 11, 2025 | $151.73 |
| Apr 14, 2025 | $154.36 |
| Apr 15, 2025 | $153.62 |
| Apr 16, 2025 | $153.91 |
| Apr 17, 2025 | $157.47 |
| Apr 21, 2025 | $156.92 |
| Apr 22, 2025 | $157.75 |
| 4 days before | 1.76% |
| 4 days after | 2.69% |
| On release day | 0.189% |
| Change in period | 4.49% |
| Release date | Jul 16, 2025 |
| Price on release | $164.78 |
| EPS estimate | $2.68 |
| EPS actual | $2.77 |
| EPS surprise | 3.36% |
| Date | Price |
|---|---|
| Jul 10, 2025 | $157.69 |
| Jul 11, 2025 | $156.90 |
| Jul 14, 2025 | $156.82 |
| Jul 15, 2025 | $155.17 |
| Jul 16, 2025 | $164.78 |
| Jul 17, 2025 | $162.98 |
| Jul 18, 2025 | $163.70 |
| Jul 21, 2025 | $164.36 |
| Jul 22, 2025 | $167.93 |
| 4 days before | 4.50% |
| 4 days after | 1.91% |
| On release day | -1.09% |
| Change in period | 6.49% |
| Release date | Oct 14, 2025 |
| Price on release | $190.85 |
| EPS estimate | $2.76 |
| EPS actual | $2.80 |
| EPS surprise | 1.45% |
| Date | Price |
|---|---|
| Oct 08, 2025 | $189.69 |
| Oct 09, 2025 | $191.08 |
| Oct 10, 2025 | $190.72 |
| Oct 13, 2025 | $190.90 |
| Oct 14, 2025 | $190.85 |
| Oct 15, 2025 | $191.17 |
| Oct 16, 2025 | $192.12 |
| Oct 17, 2025 | $193.22 |
| Oct 20, 2025 | $193.72 |
| 4 days before | 0.612% |
| 4 days after | 1.50% |
| On release day | 0.168% |
| Change in period | 2.12% |
Johnson & Johnson Earnings Call Transcript Summary of Q3 2025
Johnson & Johnson delivered a strong Q3 2025 with operational sales growth of 5.4% (worldwide sales of $24B) and continued momentum across both Innovative Medicine and MedTech. Innovative Medicine grew 5.3% (despite a large STELARA LOE headwind), driven by double‑digit growth across 11 brands including DARZALEX (+20%), TREMFYA (+40%), SPRAVATO (+61%), and the fast‑ramping CARVICTI (CAR T; +81%). New product/regulatory wins highlighted: FDA approval of Inlexo (bladder cancer), continued launches and label expansions for TREMFYA (IBD), CAPLYTA (acquired), and anticipated approvals/filings (e.g., subcutaneous Ribrovant, icotrokindra submission for psoriasis). MedTech grew 5.6% with strength in cardiovascular (Shockwave, Abiomed, electrophysiology), surgery, and vision. Management announced an intended separation (spin) of the Orthopaedics business (DePuy Synthes) to sharpen focus on six priority areas (oncology, immunology, neuroscience, cardiovascular, surgery, vision); separation targeted in 18–24 months and expected to modestly improve MedTech top‑line growth and margins. Financials: Q3 net earnings $5.2B, adjusted EPS $2.80 (up ~15.7% YoY); free cash flow YTD $14B; cash & marketable securities ~$19B and net debt ~$27B. 2025 guidance was raised: operational sales growth now 4.8%–5.3% (midpoint $93.2B) and reaffirmed FY adjusted EPS ~$10.85. Management emphasized disciplined capital allocation (opportunistic M&A, many small BD deals) and continued heavy investment in R&D and U.S. manufacturing ($55B commitment). They expressed confidence that 2026 revenue growth consensus may be conservative (they expect >5%) and reiterated commitment to long‑term accelerated growth.
